Different B-cell responses to human T-cell lymphotropic virus type I (HTLV-I) envelope synthetic peptides in HTLV-I-infected individuals |
| |
Authors: | Hiroaki Ida Akihiko Kurata Katsumi Eguchi Atsushi Kawakami Kiyoshi Migita Takaaki Fukuda Tatsufumi Nakamura Yukio Kusumoto Jay A. Berzofsky Shigenobu Nagataki |
| |
Affiliation: | (1) First Department of Internal Medicine, Nagasaki University School of Medicine, 852 Nagasaki, Japan;(2) Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, 20892 Bethesda, Maryland |
| |
Abstract: | HTLV-I (human T-cell lymphotropic virus type I) is the retrovirus related to two distinct diseases, adult T-cell leukemia/lymphoma (ATLL) and HTLV-I-associated myelopathy (HAM). We analyzed the difference in antibody activities against the viral protein and the difference in specificities of anti-HTLV-I envelope antibodies among HTLV-I-infected individuals from the same HTLV-I-endemic area using a HTLV-I-gag-env hybrid protein and HTLV-I-env-encoded synthetic peptides as antigens, respectively. The difference in the responses of IgG anti-HTLV-I envelope antibody production among HTLV-I-infected individuals was qualitative as well as quantitative. Sera from patients with HAM showed significantly higher activities of antibodies against HTLV-I-gag-env hybrid protein than sera from other HTLV-I-infected individuals including ATLL patients. The specificities of IgG anti-HTLV-I-envelope antibodies, tested on seven synthetic envelope peptides, were directed mainly against four sites, V1E7 (residues 97–111), V1E8 (191–209), and V1E9 (268–286) on gp46 and V1E1 (342–363) on gp21. Three of these sites were shown to be immunodominant T-cell sites in mice in our previous study. Whereas patients in all categories made antibodies specific for V1E1 and V1E8, only HAM patients made antibodies to the V1E7 and V1E9 epitopes, suggesting a qualitative difference in response. Whether this difference is of pathogenetic significance is not clear. The antibody activities and the specificities against the envelope protein were also analyzed in nine HTLV-I-infected polyarthritis patients because a clinical entity of specific arthritis related to HTLV-I infection has been suggested; the activities of anti-HTLV-I antibodies in sera from HTLV-I-infected polyarthritis patients were not different from the activities of the antibodies from normal HTLV-I-carriers, and no envelope peptide-specificity unique for the arthritis patients was detected. |
| |
Keywords: | Human T-cell lymphotropic virus type I (HTLV-I) human anti-HTLV-I-env antibodies synthetic peptides immunodominant sites |
本文献已被 SpringerLink 等数据库收录! |
|